ATHA

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and slow neurodegeneration. Its approach is designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is critical to normal brain function. The Company’s lead drug candidate is ATH-1105. ATH-1105 is a novel, orally available, brain-penetrant small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). ATH-1105 is in development for the potential treatment of ALS. Its ATH-1020 is a novel, orally available small molecule drug candidate designed to positively modulate the neurotrophic HGF system. It has evaluated several other compounds in preclinical discovery and development for neurodegenerative diseases and other indications.

Wall Street analysts forecast ATHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATHA is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Athira Pharma Inc revenue for the last quarter amounts to -6.87M USD, decreased -73.04 % YoY.

Athira Pharma Inc. EPS for the last quarter amounts to -4668000.00 USD, decreased -79.72 % YoY.

Athira Pharma Inc (ATHA) has 26 emplpoyees as of December 15 2025.

Today ATHA has the market capitalization of 15.26M USD.